gtb-360
mAbexperimentalTri-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2025 (NCT06594445)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
FCGR3A activator
- Myeloid cell surface antigen CD33BINDING AGENT
CD33 binding agent
- Interleukin-15BINDING AGENT
IL15 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Tri-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06594445 | Phase 1 | Jan 1, 2025 | University of Minnesota |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1